Cutaneous T-Cell Lymphoma (CTCL) Treatments
Find Cutaneous T-Cell Lymphoma (CTCL) Treatments
Medications for Cutaneous T-Cell Lymphoma (CTCL)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Cutaneous T-Cell Lymphoma (CTCL).
Found 12 Approved Drugs for Cutaneous T-Cell Lymphoma (CTCL)
Adcetris
Generic Name
Brentuximab Vedotin
Adcetris
Generic Name
Brentuximab Vedotin
Form: Injection
Method of administration: Intravenous
FDA approval date: August 25, 2011
Classification: CD30-directed Immunoconjugate
ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.
Targretin
Generic Name
Bexarotene
Targretin
Generic Name
Bexarotene
Form: Capsule, Gel
Method of administration: Oral, Topical
FDA approval date: December 29, 1999
Classification: Retinoid
TARGRETIN ® (bexarotene) Capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. TARGRETIN (bexarotene) is a retinoid indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. ( 1 )
Valchlor
Generic Name
Mechlorethamine
Valchlor
Generic Name
Mechlorethamine
Form: Gel
Method of administration: Topical
FDA approval date: November 08, 2018
Classification: Alkylating Drug
VALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. VALCHLOR is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy ( 1 ).
Istodax
Generic Name
RomiDEPsin
Istodax
Generic Name
RomiDEPsin
Form: Injection, Kit
Method of administration: Intravenous
FDA approval date: January 04, 2010
Classification: Histone Deacetylase Inhibitor
ISTODAX is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy. ISTODAX is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy ( 1 ).
Zolinza
Generic Name
Vorinostat
Zolinza
Generic Name
Vorinostat
Form: Capsule
Method of administration: Oral
FDA approval date: October 06, 2006
Classification: Histone Deacetylase Inhibitor
ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. ( 1 )
Showing 1-5 of 12
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances